12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xarelto rivaroxaban regulatory update

The European Commission approved Xarelto rivaroxaban from Bayer to treat pulmonary embolism (PE) and to prevent recurrent deep vein thrombosis (DVT) and PE. The oral Factor Xa inhibitor is approved in Europe to treat DVT, to prevent recurrent DVT and PE following an acute DVT, to prevent...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >